Last reviewed · How we verify
Dual antithrombotc therapy-2
Dual antithrombotic therapy-2, marketed by The First Affiliated Hospital with Nanjing Medical University, holds a niche position in the antithrombotic market. The key composition patent, set to expire in 2028, provides a significant period of exclusivity and competitive advantage. The primary risk lies in the lack of detailed revenue data and key trial results, which may impact investor confidence and market adoption.
At a glance
| Generic name | Dual antithrombotc therapy-2 |
|---|---|
| Also known as | DAT-2 |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: